RESEARCH ARTICLE
European Journal of Advanced Chemistry Research
www.ej-social.org
The Synthesis and Docking Study of Novel Compounds
for Variola Virus
Zuhal Gercek, Suray Jumamyradova, and Ahmet Mesut Senturk
ABSTRACT
Three novel compounds, namely, 4-amino-5-(2,3,4,5,6-pentahydroxy-1-(4oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)hexyl)-2-thioxo-2,3dihydropyrimidin-4(1H)-one SG-3, 3-methyl-5-(2,3,4,5,6-pentahydroxy-1(4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)hexyl)-2-thioxo-2,3dihydropyrimidin-4(1H)-one-(2H)-ylamino)butanoic acid SG-4 and 2-(4oxo-5-(2,3,4,5,6-pentahydroxy-1-(4-oxo-2-thioxo-1,2,3,4tetrahydropyrimidin-5-yl)hexyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)one-2-phenylacetic acid SG-6 were synthesized from easily available,
inexpensive, environmentally friendly starting materials (glucose, amino
acid and thiobarbutric acid) and characterized by 1H-NMR, 13C-NMR and
mass spectroscopy. the molecular modelling of these compounds was
studied in Crystal structure of vaccinia virus thymidylate kinase , for the
treatment of variola. Their binding motifs and drug-like properties were
investigated. Results show that all compounds confirmed appropriate
binding free energies; between –9.71 and –10.11 Kcal/mol . Since the novel
molecules have high ligand-receptor binding interactions, they can be a
powerful alternative to FDA approved drug Cidofovir.
Keywords: amino acids, glucose, molecular docking, multi component
reaction, thiobarbutric acid, virola virus.
Published Online: May 28, 2022
ISSN: 2684-4478
DOI: 10.24018/ejchem.2022.3.2.96
Z. Gercek*
Zonguldak Bülent Ecevit University,
Department of Chemistry, Turkey.
(e-mail: zuhal.gercek@beun.edu.tr)
S. Jumamyradova
Zonguldak Bülent Ecevit University,
Department of Chemistry, Turkey.
(e-mail: sjumamyradova@gmail.com)
A. M. Senturk
Istanbul Biruni University Department of
Pharmeceutical Chemistry, Faculty of
Pharmacy, Turkey.
Istanbul Medipol University, Research
Institute for Health Sciences and
Technologies (SABITA), Center of Drug
Discovery and Development, Turkey.
(e-mail: msenturk@burini.edu.tr)
*Corresponding Author
I. INTRODUCTION
The variola virus is one of the DNA virus that causes smallpox 1]. The transmission ways of the virus
between humans can be through respiratory droplets, cutaneous lesions, infected body fluids, or fomites
2]. After 12 days incubation period 3], the eruptive stage begins especially on the face and the extremities
of the limbs after 3-4 days 4]. Secondary infections accompanying the disease lead to fatal complications
5]. The smallpox mortality rates are between 30% and 40%. Humanity's struggle with smallpox has
continued almost throughout human history. Although the earliest books about smallpox were found in
China (4th century), India (7th century), and Asia (10th century) 6], the history of smallpox disease dates
back to Egypt mummies. Smallpox was eradicated in 1980 by the public vaccination campaigns organized
by World Health Organization (WHO) 7]. However, there is always the danger of the virus to return due
to inequalities in access to vaccines and vaccine hesitancy across the world. In addition, after the cessation
of vaccination, the unvaccinated young population rapidly increased, and the protective immunity in
previously vaccinated people decreased 8]. Factors such as climate changes, increased international
mobility, and profound demographic shift may cause virus-induced pandemics to start again at any time.
Pathogenic viruses can also be used as weapons by bioterrorism. Since people with immunosuppressive
diseases, skin diseases, and those used organ transplantation medications, pregnant women and heart
patients are not suitable for vaccination, the discovery of drugs that can be used in a possible smallpox
pandemic is very important research area in chemistry and pharmacy.
There are two U.S. Food and Drug Administration (FDA) -approved drugs for the treatment of smallpox;
Cidofovir or CDV-Vistide (an acyclic nucleoside phosphonate) and Tecovirimat. CDV inhibits poxvirus
replication in cell culture by interfering with viral DNA polymerase and is active in lethal poxvirus
challenge models in mice and monkeys 9]. CDV has limited use in an emergency because it must be
administered by intravenous infusion and it shows a high level of nephrotoxicity in humans [10]. The dose
selection of Tecovirimat could not be detected because of the absence of efficacy data in humans [11]. In
addition to these drugs, there are several drug candidates with some advantages and disadvantages are
described in the literature [12]-[26].
DOI: http://dx.doi.org/10.24018/ejchem.2022.3.2.96
Vol 3 | Issue 2 | May 2022
1
RESEARCH ARTICLE
European Journal of Advanced Chemistry Research
www.ej-social.org
An ideal drug should have some properties such as it can be orally administered, safe for special
populations (i.e., children, immunocompromised individuals, etc.), inexpensive to allow for large
stockpiles, and stable over long periods even under adverse conditions [27].
Here we reported the synthesis and docking study of three novel molecules, 4-amino-5-(2,3,4,5,6pentahydroxy-1-(4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)hexyl)-2-thioxo-2,3-dihydropyrimidin4(1H)-one,
3-methyl-5-(2,3,4,5,6-pentahydroxy-1-(4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5yl)hexyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one-(2H)-ylamino)butanoic acid and 2-(4-oxo-5(2,3,4,5,6-pentahydroxy-1-(4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)hexyl)-2-thioxo-2,3dihydropyrimidin-4(1H)-one-2-phenylacetic acid which can be valuable alternatives to present drugs.
The molecular skeleton of novel molecules consists of three main parts: amino acid, glucose and
thiobarbutric acid moiety (Fig. 1).
thiobarbutric acid
H
N
S
O
glucose
HN
O
N
amino acid
HN
NH
S
Fig. 1. General structure of molecules.
Carbohydrates are well-known starting material due to their several key characteristics including,
availability, highly water-solubility and optical activity. Carbohydrate derivatives have been used in
medicinal chemistry as antibiotics, antiviral drugs, protein glycosylation and glycosylation inhibitors [28].
Amino acids are the building blocks of proteins. Functional groups of amino acids can be modified by
convenient chemistry [29]-[38]. Drugs with amino acids moieties have some unique properties such as high
bioavailability, low toxicity, decrease fast metabolism.
The thiobarbutric acid moiety can be found in antibacterial 39], antiviral 40], anticancer 41],
anticonvultstant 42], antifungal 43] drugs.
II. EXPERIMENTAL
A. Materials and Instruments
All reagents and solvents were of commercial origin and used without further purification unless
otherwise noted. The 1H NMR spectra were recorded with Bruker Ultra Shield Plus ultra-long-hold-time
spectrometer using DMSO-d6 as the solvent. All chemical shifts are given in ppm relative to
tetramethylsilane (TMS) standard. Mass spectrums are taken from Waters SYNAPT G1 MS at (ESI-TOFMS) mode.
B. Chemical Syntheses
A mixture of thiobarbituric acid (2 mmol), glucose (1 mmol), amino acid (1 mmol), and p-toluenesulfonic
acid (0.1 g) in ethanol (5 mL) was stirred for 24 h at 50 C. Completion of the reaction was confirmed by
TLC (eluent EtOAc/MeOH). Then the reaction mixture was cooled to room temperature. Solid was filtered
and the remaining washed with ethanol (3 x 5 mL). Removal of the solvent under reduced pressure gave
almost pure products which were further purified by recrystallization from EtOH.
SG-3: 4-amino-5-(2,3,4,5,6-pentahydroxy-1-(4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)hexyl)2-thioxo-2,3-dihydropyrimidin-4(1H)-one: 1H NMR (DMSO-d6, 600 MHz;, ppm): 12.17, s, 2H, 12.02, s,
7H, 5.7, d, 1H, J= 3.33 Hz, 4.8, s, 1H, 4.3, d, 1H, J= 3.3 Hz, 4.0, s, 1H, 3.8, d, 1H, J= 8.5 Hz, 3.6, t, 1H,
2.3, d, 1H, J= 4.3 Hz, 2.0, s, 2H, 1.3, s, 3H, 1.2, s, 3H. 13C NMR (DMSO-d6, 150MHz;, ppm): 206, 181,
175, 166, 162, 110, 104, 85, 82, 80, 73, 68, 64, 31, 27, 26. MS: m/z: 547 (M+). Mp: 245-247 C.
DOI: http://dx.doi.org/10.24018/ejchem.2022.3.2.96
Vol 3 | Issue 2 | May 2022
2
RESEARCH ARTICLE
European Journal of Advanced Chemistry Research
www.ej-social.org
SG-4: 3-methyl-5-(2,3,4,5,6-pentahydroxy-1-(4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)hexyl)2-thioxo-2,3-dihydropyrimidin-4(1H)-one-(2H)-ylamino)butanoic acid :1H NMR (DMSO-d6, 600 MHz;,
ppm): 12.1, s, 6H, 5.7, d, 1H, J= 3.42 Hz, 4.8, s, 1H, 4.3, d, 1H, J= 3.3 Hz, 4.2, m, 1H, 4.0, s, 1H, 3.8, d,
1H, J= 8.5 Hz, 3.6, m, 1H, 3.53, s, 1H, 3.5 m, 2H, 2.0, s, 2H, 1.3, s, 3H, 1.2, s, 3H. 13C NMR (DMSO-d6,
150MHz;, ppm): 206, 175, 166, 162, 110, 104, 85, 82, 80, 73, 68, 64, 31, 27, 26. MS: m/z: 531 (M+). Mp:
164-165C. Orange solid. 45% yield.
SG-6: 2-(4-oxo-5-(2,3,4,5,6-pentahydroxy-1-(4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)hexyl)2-thioxo-2,3-dihydropyrimidin-4(1H)-one-2-phenylacetic acid :1H NMR (DMSO-d6, 600 MHz;, ppm):
12.1, s, 4H, 5.7, d, 1H, J= 3.33 Hz, 4.8, s, 1H, 4.3, d, 1H, J= 3.3 Hz, 4.0, s, 1H, 3.8, d, 1H, J= 8.5 Hz, 3.6,
t, 1H, 2.3, d, 1H, J= 4.3 Hz, 2.0, s, 2H, 1.3, s, 3H, 1.2, s, 3H. 13C NMR (DMSO-d6, 150MHz;, ppm): 206,
178, 173, 163, 162, 160, 157, 154, 147, 144, 134, 133, 124, 119, 118, 116, 115, 114, 111, 104, 96, 85, 80,
73, 68, 64, 56, 55, 31, 27. MS: m/z: 489 (M+). Mp: 231-232 C. Dark pink solid. 54% yield.
C. MolecularDocking Studies
Antiviral effects of these novel compounds have been investigated with molecular docking studies and
the best-docked poses of the molecules have been thoroughly evaluated. The best binding affinity and
receptor-ligand interaction of every compound have been assessed and well- established good interactions
of compounds withinside the receptor’s active pocket of the target receptor proteins have been demonstrated
in Table I. Based on the previous research of similar structures, we have decided to look for possible binding
motifs for smallpox virus to investigate their anti-viral activity for variola 44]. The results were compared
with FDA approved cidofovir.
III. RESULTS AND DISCUSSION
Three novel molecules, SG-3, SG-4 and SG-5, were synthesized by a multicomponent reaction (MCR)
involving glucose, different amino acids and thiobarbutric acid. Here envorimentally friendly starting
materials were converted to polyhydroxy compounds incorporating pyrimidine-fused heterocycles (PFHs).
O
OHOH
H
H O
H
H
OH
OH
H
OH + 2
S
R
HN
OH
+ H2N
N
H
O
O
PTSA
ethanol
80 C
HO
H
N
S
O
OH
HO
OH
HN
OH
N
O
amino acid
HN
NH
S
SG-3: amino acid: L-asparagine
SG-4: amino acid: L-valine
SG-6: amino acid: D,L-phenylgycine
Fig. 2. The general synthesis route.
DOI: http://dx.doi.org/10.24018/ejchem.2022.3.2.96
Vol 3 | Issue 2 | May 2022
3
RESEARCH ARTICLE
European Journal of Advanced Chemistry Research
www.ej-social.org
A. MolecularDocking Studies
Antiviral effects of novel compounds have been investigated with molecular docking studies and the
best-docked poses of the molecules have been thoroughly evaluated. The best binding affinity and receptorligand interaction of every compound have been assessed and well- established good interactions of
compounds with inside the receptor’s active pocket of the target receptor proteins have been demonstrated
in Table I. Based on the previous research of similar structures, we have decided to look for possible binding
motifs for smallpox virus to investigate their anti-viral activity for variola 44].The results were compared
with FDA approved Cidofovir.
Comp No.
TABLE I: MOLECULAR DOCKING RESULTS
Docked
aminoacid
Energy
residues (vdW
Score
interactions)
Structures
RMSD
Value
H bond (distance Å)
HO
OH
HO
H
N
S
O
HN
SG-3
THR18, ARG41,
GLU142
-9.85
0.45
O of OH with NH of LYS14
(2.081)
H of NH with Carbonyl of
ASP92 (2.167)
O of Carbonyl with NH of
ARG93 (1.91)
THR18, ARG41,
GLU145
-9.71
0.99
O of Carbonyl with NH of
ARG93 (1.746)
0.64
O of OH with NH of ARG93
(2.214)
H of OH with O of SER97
(2.144)
H of NH with O of PRO39
(1.912)
1.18
H of OH with Carbonyl of
ASP13 (1.928)
O of OH with NH of LYS17
(1.958)
O of OH with NH of ARG93
(2.058)
OH
OH
OH
N
O
O
H2N
HN
O
NH
S
HO
OH
HO
H
N
S
O
OH
HN
SG-4
OH
OH
N
O
O
HN
NH
S
HO
OH
HO
H
N
S
O
OH
HN
OH
OH
SG-6
N
O
ARG41, LEU53,
GLU142
-10.11
O
HN
NH
S
Cidofovir
ARG41, LEU53,
ARG72,
-10.51
Since the lowest negative binding energy values indicate the most powerful binding capability of the
ligand withinside the target, the conformation with the reasonably low docking energy scores is chosen. All
the compounds confirmed appropriate binding free energies towards vaccinia virus thymidylate kinase,
which have been acquired in a selection between –9.71 and –10.11 Kcal/mol.
As shown in the Fig. 3-4, compounds bonded to the active site and overlapped with reference compounds.
Our preliminary results showed that these compounds demonstrate reasonably good ligand-receptor binding
interactions.
Compound SG-6 has the lowest binding energy score with the small RMSD score in target. It also showed
strong hydrogen bonds with similar amino acid residues as explained in the tables. Figures Show that active
conformations of each compound bonded active site and overlapped with each other. The results verified
these compounds have high ligand-receptor binding interactions.
DOI: http://dx.doi.org/10.24018/ejchem.2022.3.2.96
Vol 3 | Issue 2 | May 2022
4
RESEARCH ARTICLE
European Journal of Advanced Chemistry Research
www.ej-social.org
Fig. 3. Interaction of the best-docked poses of compounds SG-3, SG-4, SG-6 and reference drug Cidofovir to 2V54 target.
Fig. 4. Superimposing poses of the best scored compounds with and without reference drug Cidofovir against 2V54.
B. Drug-Like Properties
Swiss ADME Calculation program was used to determine the structure-activity relationships of
compounds and drug-likeness rankings. The molecular weight, logP, TPSA, crossing the BBB, GI
absorption properties and sort of CYPP450 inhibition type of compounds are provided in Table II.
TABLE II: DRUG LİKENESS OF SG COMPOUNDS
Comp. No
MW (g/mol)a
LogP b
TPSA c
BBB d
GI Abs.e
Type of CYP Inh.f
SG-3
548.55
-2.77
356.06
No
Low
None
SG-4
533.58
-1.23
321.97
No
Low
None
SG-6
567.59
-1.25
321.97
No
Low
None
Cidofovir
279.19
-2.11
157.71
No
Low
None
Brincidofovir
561.69
4.16
155.94
No
Low
CYP2C19
Drug-like properties of SG compounds were calculated by Swiss ADME online software program
a
Molecular weight (recommended value <500).
b
Logarithm of the partition coefficient of the compound between n-octanol and water (recommended value <5).
c
Polar surface area (recommended value ≤140Å2).
d
Indicates whether the compound pass blod Brain Barrier or not.
e
Degree of Gastrointestinal Absorption.
f
Represent the ınhıbıtıon of CYP450 subtypes.
g
Indicates whether the compound obeys Lipinski’s Rule of Five or not.
DOI: http://dx.doi.org/10.24018/ejchem.2022.3.2.96
Rule of Fiveg
No
No
No
Yes
Yes
Vol 3 | Issue 2 | May 2022
5
RESEARCH ARTICLE
European Journal of Advanced Chemistry Research
www.ej-social.org
IV. CONCLUSIONS
The last pandemic showed us that we must always be equipped against new virus outbreaks. Viruses that
have not been seen for a long time may reappear, or some forces may use them as bioweapons. Smallpox
is a deadly viral disease that humanity has struggled with throughout history. Due to effective vaccination
it has not been seen since 1980. However, despite the possibility of a new pandemic at any moment, new
drugs have been designed and synthesized by taking into account the people who cannot use the vaccine.
Three novel compounds, namely, 4-amino-5-(2,3,4,5,6-pentahydroxy-1-(4-oxo-2-thioxo-1,2,3,4tetrahydropyrimidin-5-yl)hexyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one SG-3, 3-methyl-5-(2,3,4,5,6pentahydroxy-1-(4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)hexyl)-2-thioxo-2,3-dihydropyrimidin4(1H)-one-(2H)-ylamino)butanoic acid SG-4 and 2-(4-oxo-5-(2,3,4,5,6-pentahydroxy-1-(4-oxo-2-thioxo1,2,3,4-tetrahydropyrimidin-5-yl)hexyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one-2-phenylacetic
acid
SG-6 were synthesized, characterized and their docking calculations were performed in this research. Easily
available, inexpensive, environmentally friendly starting materials (glucose, amino acid and thiobarbutric
acid) were converted target molecules with moderate chemical yields by MCR.
In order to determine the antiviral activity of compounds, the in vivo study could not be performed
because smallpox was eradicated and, virus strains have only been kept in two repositories: the State
Research Centre for Virology and Biotechnology VECTOR, Koltsovo, Russian Federation, and the Centers
for Disease Control and Prevention (CDC), Atlanta, United States, so in-silico work was preferred.
Results show that all compounds confirmed appropriate binding free energies towards vaccinia virus
thymidylate kinase, between –9.71 and –10.11 Kcal/mol. The highest value was observed for SG-6. The
comparison of these values with Cidofovir (-10.51Kcal/mol) concluded that the novel molecules have high
ligand-receptor binding interactions. These molecules can be a powerful alternative to FDA approved drug
Cidofovir.
The high binding constants demonstrated by these three novel compounds have opened up a valuable
avenue in the synthesis of new drugs that can be used in the treatment of smallpox. The proposed drug
structure can be modified by using different sugars and different amino acids.
REFERENCES
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
Damon I. Poxviruses. In: Knipe, D.M., Howley, P.M. (Eds.), Fields Virology. sixth ed., 2014, vol. 2. Lippincott, Williams and
Wilkins, Philadelphia, pA, USA, p. 2160.
Costantino V, Kunasekaran MP, Chughtai AA, MacIntyre CR. How valid are assumptions about re-emerging smallpox? A
systematic review of parameters used in smallpox mathematical models. Mil Med., 2018; 183:e200–e207.
https://doi.org/10.1093/milmed/usx092.
Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med., 2002, 346: 1300–1308.
https://doi.org/10.1056/ NEJMra020025.
Fenner FH, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. 1988. World Health Organization, Geneva, Switzerland.
Sarkar JK, Mitra AC, Mukherjee MK, De SK, Mazumdar DG. Virus excretion in smallpox. 1. Excretion in the throat, urine, and
conjunctiva of patients. Bull World Health Organ, 1973, 48:517–522.
https://www.cdc.gov/smallpox/history/history.html#:~:text=The%20origin%20of%20smallpox%20is,century%20CE%20(Co
mmon%20Era).
Henderson DA, Inglesby T V, Bartlett J G, Ascher M S, Eitzen E, JahrlingP B, et al. Smallpox as a biological weapon: medical
and public health management. J. Am. Med. Assoc., 1999, 281, 2127–2137. 10.1001/jama.281.22.2127.
Rotz LD, Dotson DA, Damon IK, Becher JA. Advisory Committee on Immunization, P., 2001. Vaccinia (smallpox) vaccine:
recommendations of the advisory committee on immunization practices (ACIP), 2001. MMWR Recomm. Rep. (Morb. Mortal.
Wkly. Rep.) 50, 1–25 quiz CE21-27.
Bray M, Martinez M, Smee D F, Kefauver D, Thompson E, Huggins J W. Cidofovir protects mice against lethal aerosol or
intranasal cowpox virus challenge. J. Infect. Dis., 2000,181, 1019–1023. 10.1086/315190.
Cundy K.C. Clinical pharmacokinetics of the antiviral nucleotide analogs cidofovir and adefovir. Clin. Pharmacokinet, 1999,
36, 127–14.
Russo A T, Grosenbach D W, Chinsangaram J, Honeychurch K M, Long P G, Lovejoy C, et.al. An overview of tecovirimat for
smallpox treatment and expanded anti-orthopoxvirus applications. Expert Review of Anti-infective Therapy, 2021,19, 331–344.
10.1080/14787210.2020.1819791.
Russo AT, Berhanu A, Bigger CB, Prigge J, Silvera PM, Grosenbach DW, Hruby D. Co-administration of tecovirimat and
ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus
lethal monkeypox virus challenge. Vaccine, 2020, 38, 644–654. 10.1016/j.vaccine.2019.10.049.
Chan-Tack KM, Harrington PR, Choi S-Y, Myers L, O’Rear J, Seo S et.al. Assessing a drug for an eradicated human disease:
US Food and Drug Administration review of tecovirimat for the treatment of smallpox. Lancet Infect. Dis, 2019, 19, e221–e224.
10.1016/S1473-3099(18)30788-6.
Bastos LDC, De Souza FR, Guimarães AP, Sirouspour M, Guizado TRC, Forgione P, et.al. Virtual screening, docking, and
dynamics of potential new inhibitors of dihydrofolate reductase from Yersinia pestis. J. Biomol. Struct. Dyn., 2016, 34, 2184–
2198. 10.1080/07391102.2015.1110832.
Guimarães AP, de Souza FR, Oliveira A A, Gonçalves A S, de Alencastro R B, Ramalho TC, França TCC. Design of inhibitors
of thymidylate kinase from Variola virus as new selective drugs against smallpox. Eur. J. Med. Chem., 2015, 91, 72–90.
10.1016/j.ejmech.2014.09.099.
Trost L C, Rose M L, Khouri J, Keilholz L, Long J, Godin S J, Foster SA. The efficacy and pharmacokinetics of brincidofovir
for the treatment of lethal rabbitpox virus infection: A model of smallpox disease. Antivir. Res., 2015, 117, 115–121.
10.1016/j.antiviral.2015.02.007.
DOI: http://dx.doi.org/10.24018/ejchem.2022.3.2.96
Vol 3 | Issue 2 | May 2022
6
RESEARCH ARTICLE
European Journal of Advanced Chemistry Research
www.ej-social.org
[17] Damon I K, Damaso C R, McFadden G. Are We There Yet? The Smallpox Research Agenda Using Variola Virus. PLoS Pathog,
2014, 10, e1004108. 10.1371/journal.ppat.1004108.
[18] Guimarães A P, Ramalho T C, França TCC. Preventing the return of smallpox: Molecular modeling studies on thymidylate
kinase fromVariola virus. J. Biomol. Struct. Dyn., 2014, 32, 1601–1612. 10.1080/07391102.2013.830578.
[19] Prichard M N, Kern E R. Orthopoxvirus targets for the development of new antiviral agents. Antivir. Res., 2012, 94, 111–125.
10.1016/j.antiviral.2012.02.012.
[20] Garcia D R, De Souza F R, Guimarães A P, Ramalho T C, De Aguiar A P, França T C C. Design of inhibitors of thymidylate
kinase from Variola virus as new selective drugs against smallpox: Part II. J. Biomol. Struct. Dyn., 2019, 37, 4569–4579.
10.1080/07391102.2018.1554510.
[21] Merchlinsky M, Albright A, Olson V, Schiltz H, Merkeley T, Hughes C et.al. The development and approval of tecoviromat
(TPOXX®), the first antiviral against smallpox. Antivir. Res., 2019, 168, 168–174. 10.1016/j.antiviral.2019.06.005.
[22] Nuth M, Guan H, Xiao Y, Kulp J L., Parker M H, Strobel E D, Isaacs S N, et.al. Mutation and structure guided discovery of an
antiviral small molecule that mimics an essential C-Terminal tripeptide of the vaccinia D4 processivity factor. Antivir. Res.,
2018, 162, 178–185. 10.1016/j.antiviral.2018.12.011.
[23] Chaudhuri S, Symons J A, Deval J. Innovation and trends in the development and approval of antiviral medicines: 1987–2017
and beyond. Antivir. Res., 2018, 155, 76–88. 10.1016/j.antiviral.2018.05.005.
[24] Chittick G, Morrison M, Brundage T, Nichols W.G. Short-term clinical safety profile of brincidofovir: A favorable benefit–risk
proposition in the treatment of smallpox. Antivir. Res., 2017, 143, 269–277. 10.1016/j.antiviral.2017.01.009.
[25] Crump R, Korom M, Buller R M, Parker S. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of
smallpox. Antivir. Res., 2017, 139, 112–116. 10.1016/j.antiviral.2016.12.015.
[26] Grossi IM, Foster S A, Gainey M R, Krile R T, Dunn J A, et.al. Efficacy of delayed brincidofovir treatment against a lethal
rabbitpox virus challenge in New Zealand White rabbits. Antivir. Res., 2017, 143, 278–286. 10.1016/j.antiviral.2017.04.002.
[27] Kern ER. In vitro activity of potential anti-poxvirus agents. Antiviral Res., 2003, 57:35–40. 10.1016/s0166-3542(02)00198-5.
[28] Iglesias-Guerra F, Candela J I, Bautista J, Alcudia F, Vega-Pérez J M. Carbohydr. Res., 1999, 316, 71-84. 10.1016/S00086215(99)00030-0.
[29] Blaskovich M A T. Unusual Amino Acids in Medicinal Chemistry. Journal of Medicinal Chemistry, 2016, 59(24), 10807–
10836. doi:10.1021/acs.jmedchem.6b00319.
[30] Han J, Konno H, Sato T, Soloshonok VA, Izawa K. Tailor-made amino acids in the design of small-molecule blockbusterdrugs.
Eur J Med Chem, 2021,220:113448.
[31] Liu J, Han J, Izawa K, et al. Cyclic tailor-made amino acids inthe design of modern pharmaceuticals. Eur J Med Chem,
2020,208:112736.
[32] Mei H, Han J, White S, et al. Tailor-made amino acids andfluorinated motifs as prominent traits in modern pharmaceu-ticals.
Chem A Eur J., 2020, 26(50):11349-11390.
[33] Ma JS. Unnatural amino acids in drug discovery. Chim Oggi-Chem Today, 2003, 21:65-68.
[34] Qiu W, Gu X, Soloshonok VA, Carducci MD, Hruby VJ. Stereoselective synthesis of conformationally constrainedreverse turn
dipeptide mimetics. Tetrahedron Lett., 2001,42(2):145-148.
[35] Fosgerau K, Hoffmann T. Peptide therapeutics: Current statusand future directions. Drug Discov Today, 2015, 20(1):122-128.
[36] Mei H, Han J, Klika KD, et al. Applications of fluorine-containing amino acids for drug design. Eur J Med Chem,
2020,186:111826.
[37] Han J, Sorochinsky AE, Ono T, Soloshonok VA. Biomimetictransamination-a metal-free alternative to the reductive ami-nation.
Application for generalized preparation of fluorine-containing amines and amino acids. Curr Org Synth, 2011,8:281-294.
[38] Stevenazzi A, Marchini M, Sandrone G, Vergani B,Lattanzio M. Amino acidic scaffolds bearing unnatural sidechains: An old
idea generates new and versatile tools for thelife sciences. Bioorg Med Chem Lett, 2014,24(23):5349-5356.
[39] Sharma A, Noki S, Zamisa S J, Hazzah H A, Almarhoon Z M , El-Faham A. et.al. Exploiting the Thiobarbituric Acid Scaffold
for Antibacterial Activity. ChemMedChem, 2018, 19;13(18):1923-1930.doi: 10.1002/cmdc.201800414.
[40] Rajamakia S, Innitzer A, Falciani C, Tintori C, Christ F, Witvrouw M. et.al. Exploration of novel thiobarbituric acid-, rhodanineand thiohydantoin-based HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett, 2009, 19, 3615–3618.
10.1016/j.bmcl.2009.04.132.
[41] Bhatt P, Kumar M, Jha A. Design, Synthesis and Anticancer Evaluation of Oxa/Thiadiazolylhydrazones of Barbituric and
Thiobarbituric Acid: A Collective In Vitro and In Silico Approach. Chemistry Select, 2018,3, 7060–7065.
10.1002/slct.201800832.
[42] Rani A. P, Bajaj K, Srivastava V K, Chandra R, Kumara A. Synthesis of Newer Indolyl/ Phenothiazinyl Substituted 2-Oxo/
Thiobarbituric Acid Derivatives as Potent Anticonvulsant Agents. Arzneimittelforschung, 2003, 53(5): 301-306. 10.1055/s0031-1297113.
[43] Rathee P, Tonk RK, Dalal A, Ruhil MK, Kumar A. Synthesis and Application of Thiobarbituric Acid Derivatives as Antifungal
Agents. Cell Mol Biol, 2016, 62: 141. 10.4172/1165-158X.1000141.
[44] Caillat C, Topalis D, Agrofoglio L A, Pochet S, Balzarini J, Deville-Bonne D. et.al Crystal structure of poxvirus thymidylate
kinase: an unexpected dimerization has implications for antiviral therapy. Proceedings of the National Academy of Sciences,
2008, 105(44), 16900-16905.
DOI: http://dx.doi.org/10.24018/ejchem.2022.3.2.96
Vol 3 | Issue 2 | May 2022
7